Clinical Genetics · Dallas, TX
NPI
1679893010
Since 2010
Specialty
Clinical Genetics
Code 207SG0201X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
5303 Harry Hines Blvd.
Dallas, TX, 75390
Phone (214) 645-2800
Groups this clinician bills Medicare through
Medicare paid, 2024
$6,835
82 services
Medicare patients, 2024
66
Average age 58
Drug cost, 2024
$4.9M
159 prescriptions
Company payments, 2025
$147K
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Markey C McNutt II was code 99204 (office e&m - new), 32 times for 32 patients. In total Markey C McNutt II billed 82 services in 11 codes, and Medicare paid $6,835.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-09-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99204 Office E&M - New | Office | 32 | 32 | $110.04 | $3,521 |
By year: 2022 $9,859 for 110 services; 2023 $7,289 for 84 services; 2024 $6,835 for 82 services.
Medicare prescription drug claims, 2024
In 2024, the drug Markey C McNutt II prescribed most often to Medicare patients was Ravicti (Glycerol Phenylbutyrate), with 41 prescriptions and refills. In total Markey C McNutt II wrote 159 Medicare prescriptions that cost $4.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ravicti Glycerol Phenylbutyrate | 41 | 41 | Under 11 | $3.3M |
| Palynziq Pegvaliase-Pqpz | 31 | 31 | Under 11 | $792K |
| Sodium Chloride 0.9 % Sodium Chloride | 17 | 17 | Under 11 | $487 |
| Sodium Phenylbutyrate Generic | 15 | 15 | Under 11 | $67K |
| Cerdelga Eliglustat Tartrate | 12 | 12 | Under 11 | $386K |
Brand drugs: 116 claims; generic drugs: 43 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Markey C McNutt II $147K ($147K in general payments such as food, travel and fees) from 13 companies. The largest payer was Ultragenyx Pharmaceutical Inc. with $128K.
| Company | Payments | Amount |
|---|---|---|
| Ultragenyx Pharmaceutical Inc. RARE | 7 | $128K |
| BioMarin Pharmaceutical Inc. BMRN | 10 | $9,661 |
| Amicus Therapeutics, Inc. FOLD | 1 | $3,648 |
| Mirum Pharmaceuticals, Inc. MIRM | 1 | $1,625 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. 4578.T | 10 | $1,456 |
| PTC Therapeutics, Inc. PTCT | 2 | $1,028 |
| Amgen Inc. AMGN | 1 | $858 |
| Eton Pharmaceuticals, Inc. ETON | 1 | $112 |
| Genzyme Corporation SNY | 2 | $48.79 |
| IntraBio Inc | 1 | $36.99 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.